Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W. Zander AR, et al. Among authors: metzner b. Ann Oncol. 2008 Jun;19(6):1082-9. doi: 10.1093/annonc/mdn023. Epub 2008 Feb 27. Ann Oncol. 2008. PMID: 18304964 Free article. Clinical Trial.
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W. Zander AR, et al. Among authors: metzner b. J Clin Oncol. 2004 Jun 15;22(12):2273-83. doi: 10.1200/JCO.2004.07.026. Epub 2004 Apr 26. J Clin Oncol. 2004. PMID: 15111618 Clinical Trial.
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects.
Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Thiel E, Zander AR, Schulz-Kindermann F, Koch U. Scherwath A, et al. Among authors: metzner b. Ann Oncol. 2006 Mar;17(3):415-23. doi: 10.1093/annonc/mdj108. Epub 2005 Dec 15. Ann Oncol. 2006. PMID: 16357023 Free article.
High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander AR, Krüger W, Kröger N, Damon L, Königmann M, Berdel WE, Gieseking F, Schäfer-Eckart K, Möbus V, Frickhofen N, Wandt H, Illiger HJ, Metzner B, Kolbe K, Wörmann B, Trümper L, Huber C, Hossfeld DK, Maass H, Jonat W. Zander AR, et al. Among authors: metzner b. Bone Marrow Transplant. 1996 Sep;18 Suppl 1:S24-5. Bone Marrow Transplant. 1996. PMID: 8899165 Clinical Trial. No abstract available.
ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas.
Hänel M, Kröger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hänel A, Krüger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR. Hänel M, et al. Among authors: metzner b. Ann Hematol. 2000 Jun;79(6):304-11. doi: 10.1007/s002779900150. Ann Hematol. 2000. PMID: 10901609 Clinical Trial.
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR. Kröger N, et al. Among authors: metzner b. Bone Marrow Transplant. 2000 Oct;26(7):711-6. doi: 10.1038/sj.bmt.1702598. Bone Marrow Transplant. 2000. PMID: 11042650
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel WE, Kanz L, Siegert W. Rick O, et al. Among authors: metzner b. J Clin Oncol. 2001 Jan 1;19(1):81-8. doi: 10.1200/JCO.2001.19.1.81. J Clin Oncol. 2001. PMID: 11134198 Clinical Trial.
A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma.
Einsele H, Bamberg M, Budach W, Schmidberger H, Hess CF, Wörmann B, Meisner C, Straka C, Hebart H, Trümper L, Kröger N, Zander AR, Hegewisch-Becker S, Hossfeld DK, Schmidt H, Müller P, Schlimok G, Hertenstein B, Peest D, Metzner B, Frickhofen N, Kanz L, Bensinger WI. Einsele H, et al. Among authors: metzner b. Bone Marrow Transplant. 2003 Sep;32(6):593-9. doi: 10.1038/sj.bmt.1704192. Bone Marrow Transplant. 2003. PMID: 12953132 Clinical Trial.
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C; German Testicular Cancer Study Group. Schmoll HJ, et al. Among authors: metzner b. J Clin Oncol. 2003 Nov 15;21(22):4083-91. doi: 10.1200/JCO.2003.09.035. Epub 2003 Oct 20. J Clin Oncol. 2003. PMID: 14568987 Clinical Trial.
137 results